These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 22267549)
1. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549 [TBL] [Abstract][Full Text] [Related]
2. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568 [TBL] [Abstract][Full Text] [Related]
4. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714 [TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784 [TBL] [Abstract][Full Text] [Related]
6. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052 [TBL] [Abstract][Full Text] [Related]
7. What signals are generated by anti-CD20 antibody therapy? Bonavida B Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315 [TBL] [Abstract][Full Text] [Related]
8. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. Hari Y; Harashima N; Tajima Y; Harada M Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422 [TBL] [Abstract][Full Text] [Related]
9. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. Huerta-Yepez S; Baritaki S; Baay-Guzman G; Hernandez-Luna MA; Hernandez-Cueto A; Vega MI; Bonavida B Nitric Oxide; 2013 Feb; 29():17-24. PubMed ID: 23246440 [TBL] [Abstract][Full Text] [Related]
10. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. Bonavida B; Baritaki S Nitric Oxide; 2011 Jan; 24(1):1-7. PubMed ID: 20933602 [TBL] [Abstract][Full Text] [Related]
11. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303 [TBL] [Abstract][Full Text] [Related]
12. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864 [TBL] [Abstract][Full Text] [Related]
13. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Suzuki E; Umezawa K; Bonavida B Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of SNAIL sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the NF-κB pathway. Wan Z; Pan H; Liu S; Zhu J; Qi W; Fu K; Zhao T; Liang J Oncol Rep; 2015 Mar; 33(3):1560-6. PubMed ID: 25607597 [TBL] [Abstract][Full Text] [Related]
17. RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop. Bonavida B Crit Rev Oncog; 2014; 19(6):431-45. PubMed ID: 25597353 [TBL] [Abstract][Full Text] [Related]
18. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770 [TBL] [Abstract][Full Text] [Related]
19. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448 [TBL] [Abstract][Full Text] [Related]
20. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]